MedStar Authors catalog › Details for: Early mortality benefit with COVID-19 convalescent plasma: a matched control study.
Normal view MARC view ISBD view

Early mortality benefit with COVID-19 convalescent plasma: a matched control study.

by Baez, Valentina; Blumenthal, Joseph; Fernandez, Stephen J; Hettinger, Aaron Z; Shenoy, Aarthi G.
Citation: British Journal of Haematology. 192(4):706-713, 2021 02.; .Journal: British journal of haematology.Published: 2021; ; ; ISSN: 0007-1048.Full author list: Baez V; Blumenthal J; Fernandez SJ; Hettinger AZ; Shenoy AG.UI/PMID: 33482025.Subject(s): *COVID-19/th [Therapy] | *SARS-CoV-2/me [Metabolism] | Adult | Aged | Aged, 80 and over | COVID-19/bl [Blood] | COVID-19/mo [Mortality] | Disease-Free Survival | Female | Humans | Immunization, Passive | Male | Middle Aged | Retrospective Studies | Risk Factors | Survival Rate | Time FactorsInstitution(s): MedStar Harbor Hospital | MedStar Heart & Vascular Institute | MedStar Institute for Innovation | MedStar Washington Hospital Center | Washington Cancer InstituteDepartment(s): Emergency Medicine | MedicineActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1111/bjh.17272 (Click here) ORCID: Shenoy, Aarthi G https://orcid.org/0000-0002-5018-8967 (Click here) Abbreviated citation: Br J Haematol. 192(4):706-713, 2021 02; .Local Holdings: Available online through MWHC library: 1995 - 2013.Abstract: Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25.5%) compared to controls (27%, P = 0.06). Seven-day mortality was statistically better for CCP cases (9.1%) than controls (19.8%, P < 0.001) and continued at 14 days (14.8% vs. 23.6%, P = 0.01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0.02). The length of stay was longer in CCP cases than controls (14.3 days vs. 11.4 days, P < 0.001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls. Copyright (c) 2020 British Society for Haematology and John Wiley & Sons Ltd.

Powered by Koha